ORDER

Sub: Formulae to determine the quantum of compensation in case of clinical trial related injury (other than death).

As per Rule 122DAB of Drugs and Cosmetics Rules 1945, in case of clinical trial related injury/death, the trial subject is entitled to pay financial compensation. The sponsor or his representative is required to pay the financial compensation as per the order of DCG (I). As per the Rule, the financial compensation will be over and above the expenses incurred on the medical management of the trial subject. The Appendix XII of schedule Y of the Drugs and Cosmetics Rules prescribes the procedure for processing the report of the Serious Adverse Events (SAEs) including death to arrive at the cause of the death/injury to the subject and to decide the quantum of the compensation.

The Independent Expert Committee constituted for examination of SAE of death has already devised a formula being followed for determining the quantum of compensation in case of clinical trial related death.

Another committee was constituted in March 2014 under the Chairmanship of Shri R. K Jain, the then Additional Secretary & Director General (CGHS), Ministry of Health & Family Welfare, Government of India to deliberate and work out a formula to be followed to determine the quantum of compensation in case of clinical trial related injury (other than death) in accordance with the provisions of the Drugs and Cosmetics Rules. The draft formula prepared by the committee was made available for comments of public/stakeholders. After having considered the comments received, the formulae have been finalized and approved by the competent authority.

The recommendations/formulae as approved is enclosed for all concerned.

Dr. G. N. Singh
Drugs Controller General (India)

To

ISCR, IDMA, OPPI, IPA and all Concerned.

CC:
- PPS to DGHS, Nirman Bhawan, Delhi.
- PS to AS & DG (CGHS), Ministry of H&FW
- PS to JS(R), Ministry of H&FW

Annexure: Recommendation
COMPENSATION FORMULAE
(CLINICAL TRIAL)

FORMULAE TO DETERMINE THE QUANTITY OF COMPENSATION IN THE CASES OF CLINICAL TRIAL RELATED SERIOUS ADVERSE EVENTS OF INJURY OTHER THAN DEATHS OCCURRING DURING CLINICAL TRIALS

Background

As per Rule 122DAB of Drugs and Cosmetics Rules 1945, in case of clinical trial related injury/death, the trial subject is entitled for the financial compensation. The Sponsor or his representative is required to pay the compensation as per the order of DCGI. As per the rule, the financial compensation will be over and above the expenses incurred on the medical management of the trial subject. The Appendix XII of schedule Y of the Drugs and Cosmetics Rules prescribes the procedure for processing the reports of Serious Adverse Events (SAEs) including death to arrive at the cause of death/injury to the subject and to decide the quantum of compensation.

As per the procedure, in case of Clinical Trial related SAE of death, the DCGI will decide the quantum of compensation after considering the recommendation of Independent Expert Committee constituted for the purpose. In case of Clinical Trial related Serious Adverse Events other than death, (here in referred as "Clinical Trial related SAE") the DCGI will decide the quantum of compensation considering the reports of the Investigator, Sponsor and the Ethics Committee. However, there is an option to constitute expert Committee to advise the DCGI in the matter.

The independent Expert Committee constituted for examination of SAE of deaths has already devised a formula being followed for determining the quantum of compensation in case of clinical trial related death which is as under.

\[
\text{Compensation} = \left( \frac{B \times F \times R}{99.37} \right)
\]

Where,

- \(B\) = Base amount (i.e. 8 lacs)
- \(F\) = Factor depending on the age of the subject as per Annexure 1 (based on Workmen Compensation Act)
- \(R\) = Risk Factor depending on the seriousness and severity of the disease, presence of co-morbidity and duration of disease of the subject at the time of enrolment in the clinical trial between a scale of 0.5 to 4 as under:
  1. 0.50 terminally ill patient (expected survival not more than (NMT) 6 months)
  2. 1.0 Patient with high risk (expected survival between 6 to 24 months)
  3. 2.0 Patient with moderate risk
  4. 3.0 Patient with mild risk
  5. 4.0 Healthy Volunteers or subject of no risk
However, in case of patients whose expected mortality is 90% or more within 30 days, a fixed amount of Rs. 2 lacs should be given.

The Apex Committee and the Technical Committee in their 7th meeting held on 30.08.2013 and 23.08.2013 respectively, after detailed discussions agreed to the above formula for determining the quantum of compensation in cases of clinical trial related deaths. The Apex Committee in the said meeting recommended that a separate formula should also be worked out for determining the quantum of compensation in case of clinical trial related injury (other than death).

In view of the above, a committee was constituted under the Chairmanship of Shri R. K. Jain, AS & DG comprising following members to deliberate and work out a formula to be followed to determine the quantum of compensation in case of clinical trial related injury (other than death) in accordance with the provisions of the Drugs and Cosmetics Rules.

1. Dr. Y. K. Gupta, Head, Department of Pharmacology, AIIMS, Ansari Nagar, New Delhi – 110 029
2. Dr. Anil Agarwal, Professor of ENT, Maulana Azad Medical College, Bahadur Shah Zafar Marg New Delhi
3. Dr. B. T. Kaul, Prof. of Law, Delhi University, Law Centre – II, Dhauka Kaun, New Delhi – 110021
4. Dr. Mira Shiva, Coordinator, Initiative for Health, Equity and Society, A-60, HauzKhas, New Delhi - 110 016

The Committee in its first meeting held on 04-Apr-2014, discussed various criteria that could be considered for determination of quantum of compensation in case of Clinical Trial related SAE. The Committee opined that for calculation of quantum of compensation in such cases the guiding principle may be linked to the criteria considered for calculation of compensation in cases of death. The Committee also deliberated that the quantum of compensation in case of Clinical Trial related SAE should not exceed the quantum of compensation which would have been due for payment in case of death of the subject since the loss of life is the maximum injury possible.

Considering the definition of SAE, the following sequelae other than death are possible in a clinical trial subject, in which the subject shall be entitled for compensation in case the SAE is related to clinical trial.

(i) A permanent disability
(ii) Congenital anomaly or birth defect
(iii) Chronic life-threatening disease or
(iv) Reversible SAE in case it is resolved.
The Committee considered that unlike clinical trial related SAE of death, the formula for determination of compensation in each of the above 4 sequelae may be different.

Accordingly, the committee in the first meeting, deliberated separately each of the above four situations and worked out the draft formulae for determination of quantum of compensation in case of clinical trial related injury (other than death).

The draft formulae was uploaded on the CDSCO website for seeking the comments/suggestions of stakeholders.

In the second meeting held on 29th September 2014, the committee deliberated separately each of the four situations in light of the comments/suggestions received on the draft formulae and decided for revisions in two situations as under:

a) In case of SAE causing permanent disability to the subject, the quantum of compensation in case of 100% disability should be 90% of the compensation which would have been due for payment to the nominee(s) in case of death of the subject.

The quantum for less than 100% disability will be proportional to the actual percentage disability the subject has suffered.

Accordingly, committee arrived at the following formula:

\[
\text{Compensation} = \left( \frac{C \times D \times 90}{100 \times 100} \right)
\]

Where,

D = Percentage disability the subject has suffered.
C = Quantum of Compensation which would have been due for payment to the subject’s nominee(s) in case of death of the subject.

b) In case of SAE causing life-threatening disease, the quantum of compensation should be linked to the number of days of hospitalization of the subject. The compensation per day of hospitalization should be equal to the wage loss. The wage loss per day should be calculated based upon the minimum wage of the unskilled worker (in Delhi).

Since, in case of hospitalization of any patient not only the patient loses his/her wage, there will be direct or indirect losses of various kind including inconvenience, wage loss of attendant etc. The Committee decided that the compensation per day of hospitalization in such case should be double the minimum wage.
Accordingly, the committee arrived at the following formula.

\[ \text{Compensation} = 2 \times W \times N \]

Where,
- \( W \) = Minimum wage per day of the unskilled worker (in Delhi)
- \( N \) = Number of days of hospitalization

In other two situations, the committee did not consider it necessary for any revision.

**Recommended formula for determination of quantum of compensation in case of Clinical Trial related SAE other than death**

1. **SAE causing permanent disability to the subject**

   In case of SAE causing permanent disability to the subject, the Committee deliberated that so far as the quantum of compensation is concerned, 100% permanent disability to a subject may not be considered equivalent to the death of the subject. Therefore, even in case of 100% permanent disability, the quantum of compensation should be less than that for the death of the subject. After detailed deliberation the committee arrived at a decision that quantum of compensation in case of 100% disability should be 90% of the compensation which would have been due for payment to the nominee(s) in case of death of the subject. The quantum for less than 100% disability will be proportional to the actual percentage disability the subject has suffered.

   Accordingly, the following formula is recommended.

\[ \text{Compensation} = \left( \frac{C \times D \times 90}{100 \times 100} \right) \]

Where,
- \( D \) = Percentage disability the subject has suffered.
- \( C \) = Quantum of Compensation which would have been due for payment to the subject’s nominee(s) in case of death of the subject.
(ii) **SAE causing congenital anomaly or birth defect**

The committee opined that the congenital anomaly or birth defect in a baby may occur due to participation of any one or both the parents in clinical trial. Following situations may arise due to congenital anomaly or birth defect:

a) Still birth  
b) Early death due to anomaly  
c) No death but deformity which can be fully corrected through appropriate intervention  
d) Permanent disability (mental or physical)

The compensation in such cases would be a lumpsum amount such that if that amount is kept by way of fixed deposit or alike, it should bring a monthly interest amount which is approximately equivalent to half of minimum wage of the unskilled worker (in Delhi). This aspect was duly considered while fixing Rs. 8 lacs as base amount for determining the amount of compensation in case of SAE resulting into death. Hence, the quantum of compensation in such cases of SAE would be half of the base amount as per formula for determining the compensation for SAE resulting into death.

In case of birth defect leading to (c) & (d) above to any child, the medical management as long as required would be provided by the Sponsor or his representative which will be over and above the financial compensation.

(iii) **SAE causing life-threatening disease and**  
(iv) **Reversible SAE in case it is resolved**

In case of clinical trial related SAE causing life-threatening disease & reversible SAE in case it is resolved, the quantum of compensation would be linked to the number of days of hospitalization of the subject. The compensation per day of hospitalization would be equal to the wage loss. The wage loss per day would be calculated based upon the minimum wage of the unskilled worker (in Delhi).

Since, in case of hospitalization of any patient not only the patient loses his/her wage, there will be direct or indirect losses of various kind including inconvenience, wage loss of attendant. The compensation per day of hospitalization in such cases would be double the minimum wage.
Accordingly, the following formula is recommended.

\[
\text{Compensation} = 2 \times W \times N
\]

Where,
- \( W \): Minimum wage per day of the unskilled worker (in Delhi)
- \( N \): Number of days of hospitalization.
### Annexure-1

**Factor (F) for calculating the amount of compensation**

<table>
<thead>
<tr>
<th>Age</th>
<th>Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Not more than</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>228.54</td>
</tr>
<tr>
<td>17</td>
<td>227.49</td>
</tr>
<tr>
<td>18</td>
<td>226.38</td>
</tr>
<tr>
<td>19</td>
<td>225.22</td>
</tr>
<tr>
<td>20</td>
<td>224.00</td>
</tr>
<tr>
<td>21</td>
<td>222.71</td>
</tr>
<tr>
<td>22</td>
<td>221.37</td>
</tr>
<tr>
<td>23</td>
<td>219.95</td>
</tr>
<tr>
<td>24</td>
<td>218.47</td>
</tr>
<tr>
<td>25</td>
<td>216.91</td>
</tr>
<tr>
<td>26</td>
<td>215.28</td>
</tr>
<tr>
<td>27</td>
<td>213.57</td>
</tr>
<tr>
<td>28</td>
<td>211.79</td>
</tr>
<tr>
<td>29</td>
<td>209.92</td>
</tr>
<tr>
<td>30</td>
<td>207.98</td>
</tr>
<tr>
<td>31</td>
<td>205.95</td>
</tr>
<tr>
<td>32</td>
<td>203.85</td>
</tr>
<tr>
<td>33</td>
<td>201.66</td>
</tr>
<tr>
<td>34</td>
<td>199.40</td>
</tr>
</tbody>
</table>